Business
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh \"I Wish I Knew\" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy RecurrenceFocused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals (\"Salix\"), today announced its new direct-to-consumer (DTC) \"I Wish I Knew\" campaign for Xifaxan® (rifaximin), the first and only medicine FDA approved for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence in adults. Designed to raise awareness about OHE and the role of Xifaxan, \"I Wish I Knew\" seeks to educate and empower patients and caregivers to take proactive steps in managing their liver disease.In patients with cirrhosis, overt hepatic encephalopathy (OHE) is one of the key complications that is associated with worsening outcomes, morbidity, and mortality.1 In cirrhosis a damaged liver does not function normally, leading to toxins from the gut entering the bloodstream, and traveling to the brain, which can cause damage, some of which may be irreversible. These OHE episodes may present as alterations in consciousness, cognition, and behavior.2,3 Up to 80% of patients with cirrhosis will eventually develop some form of HE.1Salix remains steadfast in its mission to educate, empower and provide solutions for individuals at risk for recurrence of OHE. The new 60-second \"I Wish I Knew\" spot tells the story of a woman with a history of OHE, who reflects on her experience with symptoms of disorientation and confusion. She \"wasn't herself\" during this time, but over the course of her treatment with Xifaxan, she experienced a reduction in risk of her OHE episodes.\"We want people to know that the risk of recurring OHE episodes can be managed despite the complex nature of the condition,\" said Aimee Lenar, Executive Vice President of US Pharma at Bausch Health. \"Salix aims to spread knowledge about the progression of chronic liver disease (CLD) to cirrhosis and overt hepatic encephalopathy. Our hope is for a future where fewer patients and loved ones ‘wish they knew' cirrho...